Table of Content

1 KEY INSIGHTS

2 EXECUTIVE SUMMARY

3 CHRONIC REFRACTORY COUGH MARKET OVERVIEW AT A GLANCE
3.1 MARKET SHARE (%) DISTRIBUTION OF CHRONIC REFRACTORY COUGH IN 2018
3.2 MARKET SHARE (%) DISTRIBUTION OF CHRONIC REFRACTORY COUGH IN 2030

4 DISEASE BACKGROUND AND OVERVIEW: CHRONIC REFRACTORY COUGH (CRC)
4.1 INTRODUCTION
4.2 SIGNS AND SYMPTOMS
4.3 CAUSES
4.4 RISK FACTORS
4.5 MECHANISM OF CHRONIC COUGH
4.6 PATHOPHYSIOLOGY OF CHRONIC COUGH
4.7 SIMILARITY BETWEEN CHRONIC REFRACTORY COUGH AND OTHER NEUROPATHIC DISORDER
4.7.1 Cough hypersensitivity syndrome and Chronic Refractory Cough
4.7.2 Laryngeal hypersensitivity
4.8 PATHOGENESIS OF CHRONIC REFRACTORY COUGH
4.8.1 Cough reflex hypersensitivity
4.8.2 Peripheral sensitization
4.8.3 Central sensitization
4.8.4 Paradoxical vocal fold movement
4.9 CLINICAL FEATURES OF CRC
4.10 DIAGNOSIS
4.10.1 Primary assessment
4.10.2 Secondary assessment

5 EPIDEMIOLOGY AND PATIENT POPULATION
5.1 KEY FINDINGS
5.2 7MM PREVALENT POPULATION OF CHRONIC COUGH
5.3 7MM PREVALENT POPULATION OF CHRONIC REFRACTORY COUGH (CRC)
5.4 7MM DIAGNOSED PREVALENT POPULATION OF CHRONIC REFRACTORY COUGH (CRC)

6 COUNTRY-WISE EPIDEMIOLOGY OF CHRONIC REFRACTORY COUGH
6.1 UNITED STATES
6.1.1 Assumptions and Rationale
6.1.2 Prevalent Population of Chronic Cough in the United States
6.1.3 Gender-specific Prevalent Population of Chronic Cough in the United States
6.1.4 Prevalent Population of Chronic Refractory Cough in the United States
6.1.5 Diagnosed Prevalent Population of Chronic Refractory Cough in the United States
6.1.6 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in the United States
6.2 EU5 COUNTRIES
6.2.1 Assumptions and Rationale
6.3 GERMANY
6.3.1 Prevalent Population of Chronic Cough in Germany
6.3.2 Gender-specific Prevalent Population of Chronic Cough in Germany
6.3.3 Prevalent Population of Chronic Refractory Cough in Germany
6.3.4 Diagnosed Prevalent Population of Chronic Refractory Cough in Germany
6.3.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Germany
6.4 FRANCE
6.4.1 Prevalent Population of Chronic Cough in France
6.4.2 Gender-specific Prevalent Population of Chronic Cough in France
6.4.3 Prevalent Population of Chronic Refractory Cough in France
6.4.4 Diagnosed Prevalent Population of Chronic Refractory Cough in France
6.4.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in France
6.5 ITALY
6.5.1 Prevalent Population of Chronic Cough in Italy
6.5.2 Gender-specific Prevalent Population of Chronic Cough in Italy
6.5.3 Prevalent Population of Chronic Refractory Cough in Italy
6.5.4 Diagnosed Prevalent Population of Chronic Refractory Cough in Italy
6.5.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Italy
6.6 SPAIN
6.6.1 Prevalent Population of Chronic Cough in Spain
6.6.2 Gender-specific Prevalent Population of Chronic Cough in Spain
6.6.3 Prevalent Population of Chronic Refractory Cough in Spain
6.6.4 Diagnosed Prevalent Population of Chronic Refractory Cough in Spain
6.6.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Spain
6.7 UNITED KINGDOM
6.7.1 Prevalent Population of Chronic Cough in the United Kingdom
6.7.2 Gender-specific Prevalent Population of Chronic Cough in the United Kingdom
6.7.3 Prevalent Population of Chronic Refractory Cough in the United Kingdom
6.7.4 Diagnosed Prevalent Population of Chronic Refractory Cough in the United Kingdom
6.7.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in the United Kingdom
6.8 JAPAN
6.8.1 Assumptions and Rationale
6.8.1 Prevalent Population of Chronic Cough in Japan
6.8.2 Gender-specific Prevalent Population of Chronic Cough in Japan
6.8.3 Prevalent Population of Chronic Refractory Cough in Japan
6.8.4 Diagnosed Prevalent Population of Chronic Refractory Cough in Japan
6.8.5 Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Japan

7 RECOGNIZED ESTABLISHMENT

8 TREATMENT
8.1 TREATMENTS WITH A PERIPHERAL SITE OF ACTION
8.1.1 TRP Channels
8.1.2 Purinergic Receptors
8.1.3 Voltage-Gated Sodium Channels
8.2 TREATMENTS WITH A CENTRAL SITE OF ACTION
8.2.1 Opiates (Morphine Sulphate/Codeine/Tramadol)
8.2.2 GABA-Related Compounds (Gabapentin, Pregabalin)
8.2.3 N-Methyl-D-Aspartate (NMDA) Receptors
8.2.4 Amitriptyline
8.2.5 Tachykinin Receptor Antagonists
8.2.6 Nicotinic Acetylcholine Receptors
8.3 MANAGEMENT OF CHRONIC COUGH

9 EUROPEAN GUIDELINES ON CHRONIC COUGH
9.1 EUROPEAN RESPIRATORY SOCIETY (ERS) GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF CHRONIC COUGH IN ADULTS AND CHILDREN (2020)

10 UNITED STATES GUIDELINE ON CHRONIC REFRACTORY COUGH
10.1 TREATMENT OF UNEXPLAINED CHRONIC COUGH CHEST GUIDELINE AND EXPERT PANEL REPORT
10.2 SUMMARY OF RECOMMENDATIONS AND SUGGESTIONS

11 UNMET NEEDS

12 EMERGING DRUGS
12.1 KEY COMPETITOR
12.2 GEFAPIXANT: MERCK
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.4 Safety and Efficacy
12.2.5 Product Profile
12.3 ORVEPITANT MALEATE: NERRE THERAPEUTICS
12.3.1 Product Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.4 Safety and Efficacy
12.3.5 Product Profile
12.4 BLU-5937: BELLUS HEALTH
12.4.1 Product Description
12.4.2 Other Developmental Activities
12.4.3 Clinical Development
12.4.4 Safety and Efficacy
12.4.5 Product Profile
12.5 S-600918: SHIONOGI
12.5.1 Product Description
12.5.2 Clinical Development
12.5.3 Safety and Efficacy
12.5.4 Product Profile
12.6 BAY1817080 (ELIAPIXANT): BAYER
12.6.1 Drug Description
12.6.2 Other Development Activities
12.6.3 Clinical Development
12.6.4 Safety and Efficacy
12.6.5 Product Profile

13 MARKET ACCESS AND REIMBURSEMENT
13.1 UNITED STATES
13.2 EU5 AND JAPAN

14 CHRONIC REFRACTORY COUGH: SEVEN MAJOR MARKET ANALYSIS
14.1 KEY FINDINGS
14.2 MARKET SIZE OF CHRONIC REFRACTORY COUGH IN THE 7MM
14.3 7MM MARKET OUTLOOK
14.4 UNITED STATES MARKET SIZE
14.4.1 Total Market size of Chronic Refractory Cough
14.4.2 Market Size by Current Therapies
14.4.3 Market Size by Emerging Therapies

15 EU-5 COUNTRIES MARKET SIZE
15.1 GERMANY
15.1.1 Total Market size of Chronic Refractory Cough in Germany
15.1.2 Market Size by Current Therapies
15.1.3 Market size by Emerging Therapies
15.2 FRANCE
15.2.1 Total Market Size of Chronic Refractory Cough
15.2.2 Market Size by Current Therapies
15.2.3 Market Size by Emerging Therapies
15.3 ITALY
15.3.1 Total Market Size of Chronic Refractory Cough
15.3.2 Market Size by Current Therapies
15.3.3 Market Size by Emerging Therapies
15.4 SPAIN
15.4.1 Total Market Size of Chronic Refractory Cough
15.4.2 Market Size by Current Therapies
15.4.3 Market Size by Emerging Therapies
15.5 UNITED KINGDOM
15.5.1 Total Market Size of Chronic Refractory Cough
15.5.2 Market Size by Current Therapies
15.5.3 Market Size by Emerging Therapies
16 JAPAN MARKET SIZE
16.1.1 Total Market Size of Chronic Refractory Cough
16.1.2 Market Size by Current Therapies
16.1.3 Market Size by Emerging Therapies
17 CASE REPORT
18 MARKET DRIVERS
19 MARKET BARRIERS
20 SWOT ANALYSIS
21 KOL VIEWS
22 APPENDIX
22.1 BIBLIOGRAPHY
23 REPORT METHODOLOGY
24 DELVEINSIGHT CAPABILITIES
25 DISCLAIMER
26 ABOUT DELVEINSIGHT



List of Figures


Figure 1: Symptoms of Chronic Refractory Cough
Figure 2: Origins and neurological pathways of the cough reflex.
Figure 3: Total Prevalent Population of Chronic cough in the 7MM (2018–2030)
Figure 4: Diagnosed Prevalent Population of Chronic Refractory Cough in the 7MM (2018–2030)
Figure 5: Diagnosed Prevalent Population of CRC in the 7MM (2018–2030)
Figure 6: Prevalent Population of Chronic Cough in the United States (2018–2030)
Figure 7: Gender-specific Prevalent Population of Chronic Cough in the United States (2018–2030)
Figure 8: Prevalent Population of CRC in the United States (2018–2030)
Figure 9: Diagnosed Prevalent Population of CRC in the United States (2018–2030)
Figure 10: Diagnosed Prevalent Population of CRC in IPF patients in the United States (2018–2030)
Figure 11: Prevalent Population of Chronic Cough in Germany (2018–2030)
Figure 12: Gender-specific Prevalent Population of Chronic Cough in Germany (2018–2030)
Figure 13: Prevalent Population of CRC in Germany (2018–2030)
Figure 14: Diagnosed Prevalent Population of CRC in Children in Germany (2018–2030)
Figure 15: Diagnosed Prevalent Population of CRC in IPF patients in Germany (2018–2030)
Figure 16: Prevalent Population of CRC in France (2018–2030)
Figure 17: Gender-specific Prevalent Population of Chronic Cough in France (2018–2030)
Figure 18: Prevalent Population of CRC in France (2018–2030)
Figure 19: Diagnosed Prevalent Population of CRC in France (2018–2030)
Figure 20: Diagnosed Prevalent Population of CRC in IPF patients in France (2018–2030)
Figure 21: Prevalent Population of Chronic Cough in Italy (2018–2030)
Figure 22: Gender-specific Prevalent Population of Chronic Cough in Italy (2018–2030)
Figure 23: Prevalent Population of CRC in Italy (2018–2030)
Figure 24: Diagnosed Prevalent Population of CRC in Italy (2018–2030)
Figure 25: Diagnosed Prevalent Population of CRC in IPF patients in Italy (2018–2030)
Figure 26: Prevalent Population of Chronic Cough in Spain (2018–2030)
Figure 27: Gender-specific Prevalent Population of Chronic Cough in Spain (2018–2030)
Figure 28: Prevalent Population of CRC in Spain (2018–2030)
Figure 29: Diagnosed Prevalent Population of CRC in Spain (2018–2030)
Figure 30: Diagnosed Prevalent Population of CRC in IPF patients in Spain (2018–2030)
Figure 31: Prevalent Population of Chronic Cough in the United Kingdom (2018–2030)
Figure 32: Gender-specific Prevalent Population of Chronic Cough in the United Kingdom (2018–2030)
Figure 33: Prevalent Population of CRC in the United Kingdom (2018–2030)
Figure 34: Diagnosed Prevalent Population of CRC in the United Kingdom (2018–2030)
Figure 35: Diagnosed Prevalent Population of CRC in IPF patients in the United Kingdom (2018–2030)
Figure 36: Prevalent Population of Chronic Cough in Japan (2018–2030)
Figure 37: Gender-specific Prevalent Population of Chronic Cough in Japan (2018–2030)
Figure 38: Prevalent Population of CRC in Japan (2018–2030)
Figure 39: Diagnosed Prevalent Population of CRC in Japan (2018–2030)
Figure 40: Diagnosed Prevalent Population of CRC in IPF patients in Japan (2018–2030)
Figure 41: A proposed algorithm detailing a management approach to the patient with “difficult-to-treat” cough
Figure 42: Unmet Needs of Chronic Refractory Cough
Figure 43: Seven Major Market Size of CRC in USD Million (2018–2030)
Figure 44: Market Size of CRC in the United States, USD Millions (2018–2030)
Figure 45: Market size of CRC by Current therapies in the US, in USD Million (2018–2030)
Figure 46: Market size of CRC by emerging therapies in the US, in USD Million (2018–2030)
Figure 47: Market Size of CRC in Germany, USD Million (2018–2030)
Figure 48: Market Size of CRC by Current therapies, in Germany, in USD Million (2018–2030)
Figure 49: Market Size of CRC by emerging therapies, in Germany, in USD Million (2018–2030)
Figure 50: Market Size of CRC in France, USD Million (2018–2030)
Figure 51: Market Size of CRC by Current therapies, in France, in USD Million (2018–2030)
Figure 52: Market Size of CRC by Emerging therapies, in France, in USD Million (2018–2030)
Figure 53: Market Size of CRC in Italy, USD Million (2018–2030)
Figure 54: Market Size of CRC by Current therapies, in Italy, in USD Million (2018–2030)
Figure 55: Market Size of CRC by Emerging therapies, in Italy, in USD Million (2018–2030)
Figure 56: Market Size of CRC in Spain, USD Million (2018–2030)
Figure 57: Market Size of CRC by Current therapies in Spain, in USD Million (2018–2030)
Figure 58: Market Size of CRC by Emerging therapies in Spain, in USD Million (2018–2030)
Figure 59: Market Size of CRC in the UK, USD Million (2018–2030)
Figure 60: Market Size of CRC by Current therapies in the UK, in USD Million (2018–2030)
Figure 61: Market Size of CRC by Emerging therapies in the UK, in USD Million (2018–2030)
Figure 62: Market Size of CRC in Japan, USD Million (2018–2030)
Figure 63: Market Size of CRC by Current therapies in Japan, in USD Million (2018–2030)
Figure 64: Market Size of CRC by Emerging therapies in Japan, in USD Million (2018–2030)
Figure 65: Market Drivers
Figure 66: Market Barriers
Figure 67: Chronic Refractory Cough (CRC) SWOT Analysis


List of Tables


Table 1: Summary of CRC, Market, Epidemiology and Key Events (2018–2030)
Table 2: Total Prevalent Population of Chronic cough in the 7MM (2018–2030)
Table 3: Total Prevalent Population of Chronic Refractory Cough in the 7MM (2018–2030)
Table 4: Total Diagnosed Prevalent Population of CRC in the 7MM (2018–2030)
Table 5: Prevalent Population of Chronic Cough in the United States (2018–2030)
Table 6: Gender-specific Prevalent Population of Chronic Cough in the United States (2018–2030)
Table 7: Prevalent Population of CRC in the United States (2018–2030)
Table 8: Diagnosed Prevalent Population of CRC in the United States (2018–2030)
Table 9: Diagnosed Prevalent Population of CRC in IPF patients in the United States (2018–2030)
Table 10: Prevalent Population of Chronic Cough in Germany (2018–2030)
Table 11: Gender-specific Prevalent Population of Chronic Cough in Germany (2018–2030)
Table 12: Prevalent Population of CRC in Germany (2018–2030)
Table 13: Diagnosed Prevalent Population of CRC in Germany (2018–2030)
Table 14: Diagnosed Prevalent Population of CRC in IPF patients in Germany (2018–2030)
Table 15: Prevalent Population of Chronic Cough in France (2018–2030)
Table 16: Gender-specific Prevalent Population of Chronic Cough in France (2018–2030)
Table 17: Prevalent Population of CRC in France (2018–2030)
Table 18: Diagnosed Prevalent Population of CRC in France (2018–2030)
Table 19: Diagnosed Prevalent Population of CRC in IPF patients in France (2018–2030)
Table 20: Prevalent Population of Chronic Cough in Italy (2018–2030)
Table 21: Gender-specific Prevalent Population of Chronic Cough in Italy (2018–2030)
Table 22: Prevalent Population of CRC in Italy (2018–2030)
Table 23: Diagnosed Prevalent Population of CRC in Italy (2018–2030)
Table 24: Diagnosed Prevalent Population of CRC in IPF patients in Italy (2018–2030)
Table 25: Prevalent Population of Chronic Cough in Spain (2018–2030)
Table 26: Gender-specific Prevalent Population of Chronic Cough in Spain (2018–2030)
Table 27: Prevalent Population of CRC in Spain (2018–2030)
Table 28: Diagnosed Prevalent Population of CRC in Spain (2018–2030)
Table 29: Diagnosed Prevalent Population of CRC in IPF patients in Spain (2018–2030)
Table 30: Prevalent Population of Chronic Cough in the United Kingdom (2018–2030)
Table 31: Gender-specific Prevalent Population of Chronic Cough in the United Kingdom (2018–2030)
Table 32: Prevalent Population of CRC in the United Kingdom (2018–2030)
Table 33: Diagnosed Prevalent Population of CRC in the United Kingdom (2018–2030)
Table 34: Diagnosed Prevalent Population of CRC in IPF patients in the United Kingdom (2018–2030)
Table 35: Prevalent Population of Chronic Cough in Japan (2018–2030)
Table 36: Gender-specific Prevalent Population of Chronic Cough in Japan (2018–2030)
Table 37: Prevalent Population of CRC in Japan (2018–2030)
Table 38: Diagnosed Prevalent Population of CRC in Japan (2018–2030)
Table 39: Diagnosed Prevalent Population of CRC in IPF patients in Japan (2018–2030)
Table 40: Recommendations, strength and level of evidence, and supporting remarks for the diagnosis and treatment of chronic cough in adults and children
Table 41: Comparison of cough guidelines in relation to chronic refractory cough (CRC)
Table 42: Comparison of emerging drugs under development
Table 43: Gefapixant, Clinical Trial Description, 2021
Table 44: Orvepitant Maleate, Clinical Trial Description, 2021
Table 45: BLU-5937, Clinical Trial Description, 2021
Table 46: S-600918, Clinical Trial Description, 2021
Table 47: BAY1817080, Clinical Trial Description, 2021
Table 48: Seven Major Market Size of CRC in USD Million (2018–2030)
Table 49: Launch dates
Table 50: United States Market Size of CRC , USD Million (2018–2030)
Table 51: Market size of CRC by Current therapies in United States, in USD Million (2018–2030)
Table 52: Market size of CRC by emerging therapies in United States, in USD Million (2018–2030)
Table 53: Market Size of CRC in Germany, in USD Million (2018–2030)
Table 54: Market size of CRC by Current therapies in Germany, in USD Million (2018–2030)
Table 55: Market size of CRC by emerging therapies in Germany, in USD Million (2018–2030)
Table 56: Market Size of CRC in France, in USD Million (2018–2030)
Table 57: Market size of CRC by Current therapies in France, in USD Million (2018–2030)
Table 58: Market size of CRC by Emerging therapies in France, in USD Million (2018–2030)
Table 59: Market Size of CRC in Italy, in USD Million (2018–2030)
Table 60: Market size of CRC by Current Therapies in Italy, in USD Million (2018–2030)
Table 61: Market size of CRC by Emerging therapies in Italy, in USD Million (2018–2030)
Table 62: Market Size of CRC in Spain, in USD Million (2018–2030)
Table 63: Market size of CRC by Current therapies in Spain, in USD Million (2018–2030)
Table 64: Market size of CRC by Emerging therapies in Spain, in USD Million (2018–2030)
Table 65: Market Size of CRC in the UK, in USD Million (2018–2030)
Table 66: Market size of CRC by Current therapies in the UK, in USD Million (2018–2030)
Table 67: Market size of CRC by Emerging therapies in the UK, in USD Million (2018–2030)
Table 68: Market Size of CRC in Japan, in USD Million (2018–2030)
Table 69: Market size of CRC by Current therapies in Japan, in USD Million (2018–2030)
Table 70: Market size of CRC by Emerging therapies in Japan, in USD Million (2018–2030)